ArticleAsian Pacific journal of cancer prevention : APJCP2025
Role of miR-15b and miR-130b as Non-Invasive Biomarkers in Hepatocellular Carcinoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers, and the second cause of cancer-related deaths worldwide. MicroRNAs play a role in regulating gene expression transcriptionally and post-transcriptionally. Accordingly, they can affect cancer risk. This study aimed to highlight the diagnostic role of miR-15b and miR-130b as non-invasive biomarkers in Egyptian HCC patients. MATERIALS AND
methodsThis study included 70 patients with confirmed HCC, 35 cirrhotic patients with chronic hepatitis B or C virus infection, and 35 apparently healthy persons. Plasma miR-15b and miR-130b levels were measured by TaqMan RT-PCR assay.
resultsSignificant higher expression levels of plasma miR-15b and miR-130b were observed in HCC patients compared to hepatitis group or control group or the non-malignant group (P <0.0001 each). Combining miR-15b with AFP markedly raised the sensitivity to 91.4%, while combination of miR-130b with AFP significantly improved the specificity to 97.1 %. Combining the three markers showed excellent discriminatory power with AUC 0.959 and overall diagnostic accuracy 92.6% for differentiation between HCC from the non-malignant cases.
conclusionMiR-15b and miR-130b could serve as possible biomarkers for HCC detection, and combining these markers with AFP could markedly improve the diagnostic accuracy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.